Molecular characterization of low grade and high grade bladder cancer

Bladder cancer (BC) is the 9th most common cancer diagnosis worldwide. Low grade (LG) represents 70% of all BCs, characterized by recurrence and rare ability (10-15%) to progress to high grade (HG) and invade. The remaining 30% is high grade (HG), fast invasive BC, which is resistant to therapy. Ide...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2019-01, Vol.14 (1), p.e0210635-e0210635
Hauptverfasser:	Apollo, Alessandro, Ortenzi, Valerio, Scatena, Cristian, Zavaglia, Katia, Aretini, Paolo, Lessi, Francesca, Franceschi, Sara, Tomei, Sara, Sepich, Carlo Alberto, Viacava, Paolo, Mazzanti, Chiara Maria, Naccarato, Antonio Giuseppe
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Bioindicators Biology and Life Sciences Biomarkers Bladder Bladder cancer Cadherins - genetics Cancer Cancer therapies CD44 antigen Cluster analysis Clustering Diagnosis DNA Mutational Analysis - methods E-cadherin Female Fibroblast growth factor receptors Gene expression Gene mutation Genetic aspects Genomics Histology Humans Hyaluronan Receptors - genetics Invasiveness Keratin-20 - genetics Male Medical diagnosis Medicine and Health Sciences Metastasis Morphology Mutation Mutation - genetics Neoplasm Grading p53 Protein Pathology Receptor, Fibroblast Growth Factor, Type 3 - genetics Research and Analysis Methods Statistics Survivin Survivin - genetics Systematic review Therapeutic applications Tumor Suppressor Protein p53 - genetics Tumorigenesis Tumors Urinary Bladder - metabolism Urinary Bladder - pathology Urinary Bladder Neoplasms - genetics Urinary Bladder Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Bladder cancer (BC) is the 9th most common cancer diagnosis worldwide. Low grade (LG) represents 70% of all BCs, characterized by recurrence and rare ability (10-15%) to progress to high grade (HG) and invade. The remaining 30% is high grade (HG), fast invasive BC, which is resistant to therapy. Identifying biomarkers for predicting those tumors able to progress is a key goal for patient outcome improvement. This study focuses on the most promising prognostic markers. TP53 and FGFR3 mutational status, Survivin, CK19, CK20, E-cadherin and CD44 gene expression analysis were performed on 66 BCs. Survivin was found associated to tumor grade (p
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0210635